The aim of this study was to highlight the contribution of bone scintigraphy in the assessment of extension of osteophilic cancers in Senegal. This was a retrospective study, with a descriptive and analytical purpose, carried out over a period of four (04) years between January 01, 2018 and December 31, 2021. It focused on the files of patients who underwent bone scintigraphy for extension assessment of an osteophilic cancer during the study period. According to the study, prostate cancer was by far the most representative primary cancer (86.9%). Scintigraphy contributed in 75% of cases (362 cases) with 35% positive scintigraphy and 40% negative scintigraphy. The result was doubtful in 25% of cases (120 cases). The metastatic lesions were located preferentially at the level of the axial skeleton and only one case was of an exclusive appendicular site. More than half of patients with metastases (70%) had a poor prognosis with the SOLOWAY score greater than or equal to II. With the improvement of the nuclear imaging technical platform in Senegal (performance of SPECT/CT examinations), doubtful cases in our sample could be better explored with the advantage of adequate patient care.
References
[1]
Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660
[2]
Bouri, N.V., Ba, O., Dieme, J.L., Mbengue, M., et al. (2017) état des lieux du registre des tumeurs au Sénégal: Bilan à 6 ans d’enregistrement en ligne. Revue des Maladies Respiratoires, 34, A75. https://doi.org/10.1016/j.rmr.2016.10.156
[3]
Lipton, A. (2004) Pathophysiology of Bone Metastases: How This Knowledge May Lead to Therapeutic Intervention. The Journal of Supportive Oncology, 2, 205-213.
[4]
Macedo, F., Ladeira, K., Pinho, F., Saraiva, N., et al. (2017) Bone Metastases: An Overview. Oncology Reviews, 11, 43-49. https://doi.org/10.4081/oncol.2017.321
[5]
Rybak, L.D. and Rosenthal, D.I. (2001) Radiological Imaging for the Diagnosis of Bone Metastases. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 45, 53-64.
[6]
Pamedo, H., Marx, C., Ebert, A., Kreft, B., Ko, Y., et al. (2014) Whole Body SPECT/CT for Bone Scintigraphy: Diagnostic Value and Effect on Patient Management in Oncologic Patients. European Journal of Nuclear Medicine and Molecular Imaging, 41, 59-67. https://doi.org/10.1007/s00259-013-2532-6
[7]
Ndong, B., Mbodj, M., Mbaye, G., Ndoye, O., Bathily, E.H.A.L., et al. (2012) Place de la scintigraphie osseuse dans le bilan d’extension des métastases des cancers de la prostate au Sénégal: Étude préliminaire à propos de 45 cas. Médecine Nucléaire, 36, 586-590. https://doi.org/10.1016/j.mednuc.2012.05.012
[8]
Jalloh, M., Thia, W.G., Bathily, E.H.A.L., Dial, C., Ndoye, M., et al. (2018) Corrélation entre score de Gleason biopsique et métastases osseuses à la scintigraphie dans le cancer de la prostate. Uro’Andro, 1, 501-508.
[9]
El Ajmi, W., Ben Hmida, O., Limam, K., Hammami, H. and Sellem, A. (2020) Cancer du sein en Tunisie: Profil épidémiologique et dépistage des métastases osseuses. Médecine Nucléaire, 44, 107-135. https://doi.org/10.1016/j.mednuc.2020.01.046
[10]
Diop, O., Ndong, B., Bathily, E.A.L., Sow, D.W., Senghor, R.S., et al. (2014) Place de la scintigraphie osseuse dans le bilan d’extension des métastases osseuses du cancer du sein au Sénégal: étude préliminaire à propos de 40 cas. Revue Cames Sante, 2, 57-62.
[11]
Mayi-Tsonga, S., Belembago, E., Meyé, J., et al. (2009) Les cancers du sein au Gabon: Aspects épidémiologique, diagnostic et thérapeutique. Journal Africain du Cancer, 1, 11-15. https://doi.org/10.1007/s12558-008-0003-y
[12]
Williams, D. (2015) Thyroid Growth and Cancer. European Thyroid Journal, 4, 164-173. https://doi.org/10.1159/000437263
[13]
Davies, L. and Welch, H.G. (2014) Current Thyroid Cancer Trends in the United States. JAMA Otolaryngology—Head & Neck Surgery, 140, 317-322. https://doi.org/10.1001/jamaoto.2014.1
[14]
Zhu, C., Zheng, T., Kilfoy, B.A., et al. (2009) A Birth Cohort Analysis of the Incidence of Papillary Thyroid Carcinoma in the United States, 1973-2004. Thyroid, 19, 1061-1066. https://doi.org/10.1089/thy.2008.0342
[15]
Punnen, S., Cooperberg, M.R., D’Amico, A.V., Karakiewicz, P.I., Moul, J.W., et al. (2013) Management of Biochemical Recurrence after Primary Treatment of Prostate Cancer: A Systematic Review of the Literature. European Urology, 64, 905-915. https://doi.org/10.1016/j.eururo.2013.05.025
[16]
Boubaker, A., Houzard, C., Zouhair, A., Got, P. and Orcurto, M.V. (2011) Cancer de la prostate: Utilité de la TEP-TDM à la 18F-fluorocholine. Médecine Nucléaire, 35, 446-454. https://doi.org/10.1016/j.mednuc.2011.05.010
[17]
Husarik, D.B., Miralbell, R., Dubs, M., John, H., Giger, O.T., et al. (2008) Evaluation of [18F]-choline PET/CT for Staging and Restaging of Prostate Cancer. European Journal of Nuclear Medicine and Molecular Imaging, 35, 253-263. https://doi.org/10.1007/s00259-007-0552-9
[18]
Gauthé, M., Belissant, O., Girard, A., Zhang, Y.J., Ohnona, J., et al. (2017) TEP/TDM et récidive biologique d’adénocarcinome prostatique: apport du 68Ga-PSMA-11 lorsque la 18F-fluorocholine n’est pas contributive. Progrès en Urologie, 27, 474-481. https://doi.org/10.1016/j.purol.2017.04.004
[19]
Verburg, F.A., Pfister, D., Heidenreich, A., Vogg, A., Drude, N.I., et al. (2016) Extent of Disease in Recurrent Prostate Cancer Determined by [68Ga]PSMA-HBED-CC PET/CT in Relation to PSA Levels, PSA Doubling Time and Gleason Score. European Journal of Nuclear Medicine and Molecular Imaging, 43, 397-403. https://doi.org/10.1007/s00259-015-3240-1
[20]
Muresan, M.M., Olivier, P. and Leclere, J. (2008) Bone Metastases from Differentiated Thyroid Carcinoma. Endocrine-Related Cancer, 15, 37-49. https://doi.org/10.1677/ERC-07-0229
[21]
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J. and Thun, M. (2007) Cancer Statistics, 2007. CA: A Cancer Journal for Clinicians, 57, 43-66. https://doi.org/10.3322/canjclin.57.1.43
[22]
Rozet, F., Cornu, J.N., Cussenot, O., Fromont, G. and Hennequin, C. (2010) Cancers de la prostate cliniquement localisée à haut risque de progression. Bulletin du Cancer, 97, 1517-1536.
[23]
Joly, F. and Henry-Amar, M. (2007) Facteurs pronostiques du cancer de la prostate localisé, localement évolué et en phase métastatique. Bulletin du Cancer, 94, 35-43.
[24]
Matta-Coelho, C., Simoes-Pereira, J., Vilar, H. and Leite, V. (2019) Bone Metastases from Thyroid Carcinoma of Follicular Origin: A Single Institutional Experience. European Thyroid Journal, 8, 96-101. https://doi.org/10.1159/000494719
[25]
Paycha, F. and Richard, B. (2001) Exploration scintigraphique du squelette. Encyclopédie médico-chirurgicale, 30, 480-490.
[26]
Soloway, M.S., Hardeman, S.W., Hickey, D., Raymond, J., Todd, B., Soloway, S. and Moinuddin, M. (1988) Stratification of Patients with Metastatic Prostate Cancer Based on Extent of Disease on Initial Bone Scan. Cancer, 61, 195-202. https://doi.org/10.1002/1097-0142(19880101)61:1<195::AID-CNCR2820610133>3.0.CO;2-Y
